https://www.selleckchem.com/products/tl12-186.html
Elimination was slow with a half-life of more than 80h. Exposures increased with increasing doses. Accumulation was seen on repeated dosing. PD response, as evidenced by lower plasma levels of tumour necrosis factor-alfa (TNFα) and interleukin-4 (IL-4), was seen when compared to pre-dose values or placebo. The safety, tolerability and PK/PD profile of RP3128 demonstrates its potential to be developed in inflammatory disorders and support further clinical development (ClinicalTrials.gov number NCT02958982). The safety, tolerability and
Gefällt mir
Kommentar
Teilen
